Business
Result of General Meeting
Eco Animal Health Group plc (AIM: EAH) announced that a general meeting resulted in the approval of a special resolution authorizing the trustees of the ECO Animal Health Group Employee Benefit Trust to begin limited on-market repurchases of the company's ordinary shares (5 pence each). Voting results are available on the company's website. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n21 August 2025\n\nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nResult of General Meeting\nECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that at a General Meeting held earlier today, the single special resolution proposed was duly passed.\nAs a result, trustees of the ECO Animal Health Group Employee Benefit Trust will shortly commence limited on-market purchases of the Company's ordinary shares of 5 pence each.\nVoting results from the General Meeting will be made available on the Company's website at https://ecoanimalhealth.com/investors/.\n-Ends-\n \nContacts\n\n\n\n\n \nECO Animal Health Group plc\nDavid Hallas (Chief Executive Officer)\nChristopher Wilks (Chief Financial Officer)\n \n\n\n 020 8447 8899\n\n\n\n\nICR Healthcare (Financial PR)\nMary-Jane Elliott\nJessica Hodgson\n \n\n\n020 3709 5700\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Joint Broker)\nPhilip Davies\nSam Butcher\n \n\n\n020 7496 3000\n\n\n\n\nInvestec (Joint Broker)\nGary Clarence\nLydia Zychowska\n \n\n\n020 7597 5970\n \n \n \n\n\n\n\nEquity Development\nHannah Crowe\nMatt Evans\n\n\n020 7065 2692\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nAbout ECO Animal Health\nECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.\n \nHeadquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.\n \nOur lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.\n \nClick here for more information: https://ecoanimalhealth.com\n \n\n","length":6199,"tagName":"div"}]